Close
FINDING CURES TOGETHER<sup>SM</sup>
Keith T. Flaherty, MD

Keith T. Flaherty, MD
(2019-2022)
Director of Developmental Therapeutics
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Dr. Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center, and Professor of Medicine at Harvard Medical School.  As described in the more than 300 peer reviewed primary research reports he has authored or co-authored, Dr. Flaherty and colleagues made several seminal observations that have defined the treatment of melanoma when they established the efficacy of BRAF, MEK and combined BRAF/MEK inhibition in patients with metastatic melanoma in a series of New England Journal of Medicine articles for which Dr. Flaherty was the first author.  Dr. Flaherty also has been a leader in assessing and identifying mechanisms of de novo and acquired resistance to BRAF
inhibitor therapy and clinically evaluating next generation inhibitors, work that has had implications for resistance to targeted therapy regimens used to treat other malignant diseases.  He serves as editor-in-chief of Clinical Cancer Research.